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Abstract
Background: Allergic sensitization in children and allergic diseases arising therefrom are increasing for decades.
Several interventions, functional foods, pro- and prebiotics, vitamins are proposed for the prevention of allergies
and they can’t be uncritically adopted.
Objective: This Consensus document was developed by the Italian Society of Preventive and Social Paediatrics and
the Italian Society of Paediatric Allergy and Immunology.
The aim is to provide updated recommendations regarding allergy prevention in children.
Methods: The document has been issued by a multidisciplinary expert panel and it is intended to be mainly
directed to primary care paediatricians.
It includes 19 questions which have been preliminarily considered relevant by the panel. Relatively to each
question, a literature search has been performed, according to the Italian National Guideline Program.
Methodology, and a brief summary of the available literature data, has been provided.
Many topics have been analyzed including the role of mother’s diet restriction, use of breast/formula/hydrolyzed
milk; timing of introduction of complementary foods, role (if any) of probiotics, prebiotics, vitamins, exposure to
dust mites, animals and to tobacco smoke.
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Results: Some preventive interventions have a strong level of recommendation. (e.g., the dehumidifier to reduce
exposure to mite allergens). With regard to other types of intervention, such as the use of partially and extensively
hydrolyzed formulas, the document underlines the lack of evidence of effectiveness.
No preventive effect of dietary supplementation with polyunsaturated fatty acids, vitamins or minerals has been
demonstrated.
There is no preventive effect of probiotics on asthma, rhinitis and allergic diseases. It has demonstrated a modest
effect, but steady, in the prevention of atopic dermatitis.
Conclusions: The recommendations of the Consensus are based on a careful analysis of the evidence available.
The lack of evidence of efficacy does not necessarily imply that some interventions may not be effective, but
currently they can’t be recommended.
Keywords: Allergy, Children, Prevention, Consensus
Background
A peak in allergic, especially respiratory, disease prevalence
has been recently reported in Western countries [1–5]. As
an example, a multicenter study conducted in the Italy, as
part of the European Community Respiratory Health
Survey (ECRHS), reported a rhinitis prevalence of 18.5 %
among children, with an increase of more than 50 % over
the previous decades [6]. Bronchial asthma prevalence has
increased, as well, as reported by The International Study
of Allergy and Asthma in Childhood (ISFAC) [7].
Rhinitis and asthma affect both the quality of life in rela-
tion to health (as measured by Health-Related Quality Of
Life (HRQOL) and the cost of treatment. Several studies
show that rhinitis has negative effects on the activities of
the patient’s everyday life at home, school and work [8, 9].
The questionnaire designed to measure the effect of rhin-
itis on quality of life (QoL) showed patients with sleep
problems, emotional issues and limitations in their activ-
ities and social relationships [10]. Similarly, studies have
been carried out to assess the QoL of children and adoles-
cents with asthma through the use of specific question-
naires such as the Paediatric Asthma Quality Of Life
Questionnaire (PAQLQ), the Adolescent Asthma Quality
of Life Questionnaire (FAQLQ) or the Rhinasthma QoL
Questionnaire [11, 12]. Studies of the impact of asthma on
QoL have reported that asthma causes greater limitation
of physical activity and has greater influence over the
emotional sphere in girls while the PAQLQ score de-
creases with the progression of disease severity [13, 14]. In
contrast, a recent meta-analysis of 3550 children with
asthma demonstrated that many patients were suffering
from depression and anxiety disorders, regardless of the
level of severity of their disease [15].
In countries such as Australia, the United States and UK,
the past decade has been marked by a “second wave” of al-
lergic disease in the form of food allergy (FA) [1]. Reliable
data on this prevalence in other European countries are
lacking [16]. “Perceived” FAs are often not confirmed using
diagnostic tests. In one study an incidence between 12.4
and 25 % in self-reported FA is estimated, whereas confirm-
ation by oral provocation test (OPT) only occurred in 1.5–
3.5 % of cases [17]. In general, FA is more common among
children with an incidence of 5–8 %, as compared to 1–2 %
in adults [18]. Few epidemiological studies make use of the
diagnostic gold standard, the double-blind, placebo-
controlled food challenge. Thus, more research is needed
for a more accurate determination of the prevalence and in-
cidence of FA in the paediatric population [16]. FA repre-
sents a significant problem in terms of morbidity and
mortality if one considers that foods are the most import-
ant trigger of anaphylaxis in children, although the preva-
lence of fatal anaphylaxis is 0.001 % [19].
The results of 10 studies from Europe suggest an inci-
dence of anaphylaxis ranging between 1.5 and 7.9/
100,000/year [19]. Studies conducted in the UK reveal an
increase in hospital admissions for anaphylaxis over the
last two decades [19]. Three European studies show a
prevalence of anaphylaxis of 0.3 % (95 % CI: 0.1–0.5 %)
[19]. In the last 10 years, studies to assess the impact of
FA on the quality of life of patients have been published.
The disease has a significant effect on the quality of life of
children and their families and on healthcare costs, both
in numbers of outpatient visits and repeated admission to
emergency departments. Moreover, elimination diets can
trigger authentic food phobias among parents, and some-
times consequent eating disorders, especially if the disease
is severe, as it is in particularly sensitive patients at risk of
anaphylaxis even with small ingested doses [20, 21].
For all these reasons, many studies have evaluated the
possibility of primary prevention of allergic diseases for
children at high risk of developing them. The objective
of the present Consensus is to define the evidence re-
garding the actual impact that environmental, behav-
ioural and nutritional preventive measures may exert on
the incidence and prevalence of respiratory and food
allergies.
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Methods
In the present document a children at risk of allergic
disease has been defined as any child with at least one
first-degree relative (parent or sibling) suffering from
atopic disease.
Search strategy
Using the Consensus Conference method based on the
National Institutes of Health and the Italian National
Programme Guidelines (Piano Nazionale Linee Guida,
PNLG), relevant publications in English were identified
by a systematic review of MEDLINE and the Cochrane
Database of Systematic Reviews from their inception
until December 31, 2014. The search strategy was
“children [Title/Abstract] OR pediatric [Title/Abstract]
AND allergy prevention [Title/Abstract] OR prevention
[Title/Abstract] OR allergy [Title/Abstract] AND asthma
[Title/Abstract] OR rhinitis [Title/Abstract] or food al-
lergy drug [Title/Abstract] AND English [lang]).” The
Working Group agreed on a list of clinical questions
(listed below) and provided specific additional search
strategies for each questions.
The analysis and evaluation of the Guidelines was
made according to the following minimum criteria of
validity: multidisciplinary panel, systematic search for
evidence, grading of recommendations.
Analysis of Systematic Reviews, Randomized Controlled
Trials and Observational Studies were made using the
AMSTAR (Assessment of Multiple Systematic Reviews)
tool [22], the Cochrane Risk of Bias Tool [23] and the
Newcastle Ottawa Scale [24] respectively.
Question 1. Should exclusive breastfeeding be pro-
moted against infant formula (formula) for the pre-
vention of allergic diseases in high risk infants?
Introduction
Breastfeeding is associated with several beneficial
effects on mother and child health and is therefore rec-
ommended for all infants [25]. Several potential, mecha-
nisms may be linked to the prevention of allergic disease
through exclusive breastfeeding, such as limited expos-
ure to exogenous antigens, protection against infections,
promotion of the maturation of the gastrointestinal
mucosa, development of “beneficial” gut microbiota and
carrier substances for immunomodulatory and anti-
inflammatory actions (e.g. n-3 LCPUFA) [26].
The association between breastfeeding and the preven-
tion of allergic disease has been frequently studied and
has often been debated in the last 70 years. Some studies
have shown a protective effect, others failed to show any
effect and others still have demonstrated a predisposing
effect. Despite conflicting and controversial data in the
literature, this should not be interpreted as meaning
that breastfeeding has no noticeable effect. In fact, the
association between breastfeeding and prevention of
allergic disease remains inadequately studied and their
interactions are complex. The existing randomised,
double-blinded studies cannot be included in system-
atic reviews and meta-analyses and most published
studies are retrospective. Furthermore, the definition of
breastfeeding itself is imprecise [27].
In particular, many studies do not distinguish be-
tween exclusive and non-exclusive breastfeeding.
Moreover, the nomenclature to define allergic out-
comes is often used incorrectly (wheezing and
asthma). Finally, the investigation of the association
between breastfeeding and allergy prevention can be
complicated by the presence of polymorphisms in the
fatty acid desaturase (FADS) gene cluster. The result-
ing enzymatic activity leads to the production of long
chain fatty acids (LCPUFA) and influences the levels
of LCPUFA in mother’s milk, thereby modulating the
association [28].
In 1988, Kramer developed 12 standards for the de-
sign and analysis of studies assessing the association
between breastfeeding and allergic disease. These
included prospective design, sufficient duration of
exclusive breastfeeding, specific definition of allergy
outcomes for analysis, the evaluation of effects on the
at-risk population and ensuring adequate statistical
power [29]. To date, however, no published study has
met these criteria, and both the association and the
controversy between breastfeeding and allergy remain
unresolved.
Summary of literature data
Effect on allergic rhinitis
A meta-analysis of prospective studies found a protect-
ive effect of exclusive breastfeeding of 3 months’ dur-
ation or more to be close to statistical significance in the
general population (OR 0.74; 95 % CI) 0.54–1.01 but not
in children with a family history of atopic disease (OR
0.87; 0.48–1.58 95 % CI) [30]. Of the later studies con-
ducted in this field, only one appears to be prospective
and observed reduced risk of allergic rhinitis (OR 0.8;
0.6–0.9 95 % CI) at 3 years of life in an African-
American paediatric population at risk [31].
Effect on wheezing and asthma
Breastfeeding exclusively for the first 3–4 months of
life appears to be associated with a reduction in episodes
of wheezing caused by an upper airway infection in the
first 4 years of life [32]. Wheezing episodes after 6 years
may be symptoms of allergic asthma. In this setting, the
results of the study on a protective effect of breastfeed-
ing remain controversial [32].
Two meta-analyses of prospective studies also re-
ported controversial results regarding the protective
effect of 3 or more months of exclusive breastfeeding
against the risk of developing asthma in individual chil-
dren at risk of atopy [33, 34]. Some studies even suggest
that exclusive breastfeeding for 3 months increases the
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incidence of asthma after 14 years of age in children
with atopic risk factors [32].
Recently, a study has shown that the prevalence of
asthma in 10 years of life is reduced only in popula-
tions of children who were exclusively breastfed for
at least 3 months and who were carriers of at least
one minor allele polymorphism in the FADS gene
cluster [28]. Children homozygotes for the major al-
lele failed to benefit from exclusive breastfeeding
altogether [28].
Effect on food allergy
There is insufficient evidence to conclude about a
benefit of breastfeeding in the prevention of food
allergy in infants with an atopic risk [35–37]. A
multidisciplinary review, however, concluded that
breastfeeding seems to exert a protective effect, par-
ticularly amid children at risk [38]. A prospective,
randomised clinical trial in preterm infants reported a
lower cumulative incidence of cow’s milk protein al-
lergy (not food allergy in general) 18 months after
term. This marked reduction especially concerned
events such as allergic eczema. Infants who had been
fed with breast milk from a human milk bank for
more than 4 months performed better that their peers
on a diet of term and preterm infant formula [39]. In
a more recent systematic review two cohort studies
showed, that exclusive breastfeeding had no beneficial
effect or was associated with an increased risk for
allergy in the population at risk for atopic disease
[37, 40, 41]. Wetzig et al. showed that exclusive
breastfeeding for 5 months or longer was associated
with greater egg sensitisation in 1 year, but did not
include any data about food allergy [41].
Effect on atopic dermatitis
In one meta-analysis, exclusive breastfeeding for
3 months rather than formula was associated with a
greater reduction in the incidence of atopic dermatitis
[42, 43]. However, a subsequent systematic review and
meta-analysis found no effect of breastfeeding, and re-
moved one controversial study from the analysis [25].
Box 1. Breastfeeding definition
In conclusion, although the data from the literature
remain controversial and no single protective effect of
breastfeeding can be shown to be effective against the
onset of allergic disease, an exclusive breastfeeding regi-
men for 6 months should be promoted in view of the
known and recognized nutritional and immunological
benefits of breast milk.
Recommendation. Exclusive breastfeeding (possibly
for 6 months and for at least 4 months) should be
promoted for the known and recognized nutritional
and immunological benefits of breast milk.
Weaning
Question 2. Is weaning between the 4th and 6th
month of life recommended for the prevention of
allergic diseases in children?
Introduction
The World Health Organization recommends exclu-
sive breastfeeding for the first 6 months of life [44].
The American Academy of Pediatrics recommends
the introduction of “complementary foods” no earlier
than 4 months and recommends exclusive breastfeed-
ing as indicated for up to 6 months [45]. Early expos-
ure to solid foods (<4 months) has been blamed for
the development of allergic disease in the past and
especially among patients with atopic dermatitis. A
paradigm shift is currently under way with the spread
of oral tolerance induction as a concept in allergy
therapy. Studying the introduction of “complementary
foods” after at least 4 months of exclusive breastfeed-
ing may lead to a reduction in the prevalence of food
allergy.
Knowledge-based approaches
Several cohort studies, such as GINI, LISA or KOALA
have failed to capture an effect of delaying the intro-
duction of solid foods in terms of food allergy preva-
lence [46–48]. The strategy of delayed solid food
introduction until the 6th month does not seem to
confer prevention benefits, as shown in two cohort
studies the quality of evidence of which is rated as
low [49, 50].
Introduction of potentially allergenic foods (cow’s
milk, eggs, fish, nuts)
There are two randomised, controlled clinical trials
that show that early exposure to cow’s milk protein in
the first few days of life is not associated with an in-
creased risk of food allergy [51–53].
However, in one of these studies the diagnostic criteria
for food allergy do not include confirmation by OFC
(Oral Food Challenge) and, in the other, the symptoms
are unspecific and food allergy data are not reported.
Another randomised trial and a cohort study have
shown an increased risk of cow's milk protein allergy
with neonatal exposure to these proteins, especially
among children at risk of atopy [51–55].
Exclusive breastfeeding: The infant who receives only human milk
(including donor milk). Oral rehydration solution (ORS), syrups
(vitamins, minerals) and medicines are allowed but nothing else.
Predominant breastfeeding: the predominant source of nourishment
is breast milk. Water and water-based drinks, oral rehydration salts
solution, drops and syrups (vitamins, minerals, medicines) are allowed
but nothing else.
Infant formula food alone can satisfy the nutritional requirements of
the first 6 months of life (Directive 2006/141/EC implemented by
Ministerial Decree n. 82 of 9th April 2009).
Follow-on formula: food constituting the principal liquid element
of the diet of infants, after diversification at 6 months of age
(Directive 2006/141/EC, implemented by Ministerial Decree n. 82
of 9th April 2009).
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In a prospective observational cohort study of 13,019
children, the relative risk of those exposed to the CMP
in the first 15 days of life than those exposed after
15 days = 0.045 (in practice it would be about 20 times
less likely to develop a CMP sensitization if their intro-
duction is done before 15 days of life) [56]. About the
introduction of hen’s egg, one observational study re-
ported an increased risk of allergy with more delayed
introduction (>9 months) even after adjusting for
confounding factors [57]. Regarding the fish and egg
introduction, current international nutritional recom-
mendations for the general population do not suggest
delayed introduction (>9 months) but actively indicate
exposure within a short time of the introduction of
solid foods, preferably while the infant is breastfed
[58, 59]. This is an important point for emphasis
from an allergy as well as nutritional point of view
[60]. In fact, the introduction of such foods, along
with breastfeeding, can maintain the profile of the
most beneficial nutrient intake, since associated with
a lower intake of protein, the greater contribution of
LCPUFA, especially DHA, respect to only meat and
cheese [60]. The recently published results of two RCTs
(LEAP [61] and EAT study [62]) would seem to prove the
preventive efficacy of early exposure to allergenic foods
(peanuts, fish, CMP, egg, sesame). In fact, in the LEAP
study, the “early ” exposure was between 4 and 11 months
and the EAT study is burdened by many biases including:
the very low compliance to intervention (just 30–40 %),
diagnostic confirmation with OFC 6–12 months after
allergic reactions, non-registration of allergy cases be-
tween 3 and 6 months.
Box 2: Definition of “complementary foods”.
In conclusion, available scientific evidence does not
allow making specific recommendations about the
timing of the introduction of complementary foods for
the prevention of allergic disease. Regarding the timing
of introduction of potentially allergenic foods, once
“complementary foods” have been introduced into the
diet, current evidence does not justify either delaying or
encouraging exposure without reference to individual
atopic risk.
Recommendation The introduction of “comple-
mentary foods” is recommended after the 4th month
and if possible after the sixth, regardless of the mode
of feeding and atopic risk.
Recommendation Once feeding “complementary
foods” has been initiated, it is recommended to
introduce potentially allergenic foods in the same
way in the diet of children with or without an al-
lergic risk.
Partially hydrolysed formula (pHF), extensively
hydrolysed formula (eHF) and functional foods
Question 3. In children at risk, in case of hypo/aga-
lattia maternal, you must do prevention with formulas
Partially hydrolyzed (partially Hydrolyzed Formulas -
PHF) vs infant formula (Formula) to prevent the
allergic disease?
Question 4. In children at risk, in case of hypo/ma-
ternal agalattia, you have to make prevention with
extensively hydrolyzed formula (extensively Hydro-
lyzed Formulas - eHF) vs infant formula (Formula) to
prevent the allergic disease?
Introduction
The aim of the present section is to define recom-
mendations for the use of partially hydrolysed formula
(PHF) and extensively hydrolysed (eHF) formulas and
of some functional foods (ω3 and ω6 polyunsaturated
fatty acids, vitamins and minerals) for the primary
prevention of allergy. For this purpose, a preliminary
evaluation of the available scientific evidence on the
safety and efficacy data of the interventions was car-
ried out.
NB: The composition of the formulas available in Italy
under the designation of “hypoallergenic” or HA corre-
sponds to partially hydrolysed milks (“PHF” in this Con-
sensus document).
Partially hydrolysed (PHF) and extensively hydro-
lysed (eHF) formula
Exposure to allergens early in life during pregnancy
or in infanthood is critical for the development of
allergies. Scientific research has therefore focused on
children’s diets which involve early exposure to aller-
gens and can easily be modified. Preventive measures
tested for allergies and food allergy in particular, have
included maternal allergen avoidance during preg-
nancy and/or breastfeeding, exclusive breastfeeding
for a more or less prolonged period and avoidance of
potential allergens—both dietary and environmental—
during the first year of life and beyond. Allergy is a
specific reaction to a normally harmless protein
(allergen).
Partial and extensive hydrolysates are manufactured by
modifying the allergenic protein content of milk in order
to prevent sensitisation. These formulas can be derived
from cow’s milk proteins (serum protein or casein) and
soy and they are produced by processes of partial or ex-
tensive enzymatic digestion that can break the native
proteins into peptides of different sizes [63]. The formu-
las derived from cow’s milk (CMF) contain whole
“Complementary foods”: all liquid, semi-solid and solid foods which differ
from breast milk and formula milk. World Health Organization. Indicators
for assessing infant and young child feeding practices Part 1: Definitions.
Geneva: World Health Organization, 2008, Available from: http://
whqlibdoc.who.int/publications/2008/9789241596664_eng.pdf
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proteins ranging in size from 14 kD (α-lactalbumin) to
67 kD (serum albumin) [64]. There is no agreement
about defining a formula as partially, in contrast to ex-
tensively, hydrolysed according to the size of its con-
stituent peptides. By convention, eHF contains only
peptides ≤3 kD, while PHF contains only peptides ≤5 kD.
In practice, however, in both PHF and eHF peptide size
can range widely, with PHF including 18 % of its
peptides > 6 kD, while eHF may include up to 5 % of
peptides > 3.5 kD [65]. The 10–70 kD (and particularly the
10–40 kD) size range has been directly associated to anti-
genicity in peptides [66].
Note on methodology
Please refer to the relevant section for an outline of
the search strategy. The evaluation of the scientific
evidence is shown in the Appendix. The population se-
lected for preventive intervention includes by definition
children at risk of allergies receiving formula milk in
addition to, or in place of, breast milk.
As with other prevention studies, outcomes of interest
considered were:
 Allergy (any)
 Food allergy (FA)
 Allergic rhinitis
 Asthma
 Atopic eczema
 Adverse events
 Nutritional status
The latest updates of evidence-based guidelines were
consulted:
 NIAID5 (National Institute of Allergy and Infectious
Diseases) 2010
 EAACI (European Academy of Allergy and Clinical
Immunology) 2013 – alimentary allergy [68]
 ARIA (Allergic Rhinitis and its impact on Asthma)
Italian Guideline 2013 – Rhinitis [69]
 GINA (Global Initiative for Asthma) 2012 [70]
 BTS (British Thoracic Society)/SIGN 2012 –
Asthma [71]
 SIGN (Scottish Intercollegiate Guidelines Network)
2011 [72]
 ASCIA (Australian Society of Clinical Immunology
and Allergy) 2016 [73]
 FAD (American Academy of Dermatology) 2014 –
Atopic eczema [74]
The meta-analyses and primary studies not included
in systematic reviews because they were published
after the closing date of the literature search were
analysed only if considered of sufficient methodo-
logical quality.
Previous recommendations
The guidelines of both the NIAID (2010) and the
EAACI (2013) recommended the use of hydrolysates
designed for the treatment of food allergy for children
at risk, instead of standard infant formula (strength of
recommendation B). The 2010 NIAID guidelines spe-
cify that cost and availability should be considered as
counter-indicative. The 202 BTS/SIGN and GINA
guidelines do not recommend hydrolysed formula for
prevention and acknowledge only a protective effect
in breastfeeding. The 2013 ARIA guidelines do not
include recommendations for the prevention of rhin-
itis. The 2011SIGN, which found limited evidence of
a protective effect of eHF when compared to CMF,
do not report any specific recommendation for the
prevention of atopic dermatitis, while eHF in prefer-
ence to breast milk is specifically not recommended.
Even the 2014 ADF guidelines consider that there is
insufficient scientific evidence to recommend specific
preventive interventions (dietary or otherwise) for the
primary prevention of AD.
Results
Results are reported for individual allergic diseases.
Three systematic reviews (SR) published between 2009
and 2014 were included for these questions [75–77].
Two SR with meta-analysis evaluated prevention
against the development of allergic diseases, as a
group and individually [75, 76]. One systematic re-
view without meta-analysis only evaluated FA preven-
tion and included the results of primary studies and
SR published before 2009 [77]. It also considered a
2012 US Food and Drug Administration review of
the scientific evidence in favour of the qualified
health claim of partially hydrolysed whey-protein for-
mula (W-PHF) in regard of risk reduction for atopic
dermatitis [78].
Most studies of the use of partially and extensively
hydrolysed formulas have low methodological quality in
respect of one or more of the following factors: incorrect
randomisation procedure, limited sample size, loss to
follow-up > 20 %, surrogate or irrelevant clinical outcomes
(e.g. sensitisation, atopic dermatitis) and FA diagnosis
unconfirmed at OFC.
The few randomised studies with clinically relevant
outcomes (and a diagnosis of FA confirmed at OFC) car-
ried out in children at risk showed mixed results. Sys-
tematic reviews have shown conflicting data at this
regards [67–69]. At any rate, current evidence does not
substantiate a preventive effect of PHF formula on the
development of food allergy in infants [70, 73, 74].
One study reported a lower risk of developing, specif-
ically, cow’s milk protein allergy (CMPA), but it was
conducted in a sample of only 67 children. The assess-
ment of the overall impact of other allergic diseases
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showed no preventive effect, neither in early childhood
nor in later life [79].
Some meta-analyses fail to show a preventive effect
on the incidence of atopic dermatitis either in early
childhood or later [75]. In other studies, a certain
preventive effect is reported but the data should be
treated with caution [76]. The number needed to
treat is 17 [9–119], i.e. 17 children must be treated,
in order to prevent one case of atopic dermatitis. Few
studies of rhinitis and asthma prevention have been
carried out and these failed to establish a protective
effect. The comparison between partially and exten-
sively hydrolysed formulas for the prevention of FA
or CMPA apparently favours eHF but the number-
needed-to-treat estimates for eHF (NNT = 14) in FA
and NNT = 25 in CMPA are fraught with inaccuracies
and are difficult to apply to clinical practice settings.
All studies concur in denying a preventive effect of
soy milk [77, 79]. The higher cost of alternative for-
mula (about double that of CMF) and its inferior pal-
atability are well documented [71, 72, 80, 81]. In a
meta-analysis, Osborn included two studies of 46 pre-
term infants to assess weight gain in relation to the
use of hydrolysed formula.
Overall evaluation
Recommendations about the primary prevention of al-
lergies cannot be separated from the assessment of the
methodological quality of clinical studies and from the
clinical relevance of their results, on which some specific
criteria exert an influence. For example, the diagnosis of
FA requires confirmation with OFC, except in the pres-
ence of an anaphylactic reaction. Studies that include
diagnosis by “self-report”, or are based on symptoms of
allergy and/or sensitisation and allergy, are considered of
lower validity. They are often included in systematic re-
views and the recommendations of some guidelines (GL)
are based on them.
Finally, the conclusions drawn from the evidence must
be integrated in a cost-effectiveness analysis, taking into
account the following factors:
a. absolute effectiveness of preventive interventions;
b. health gain expected (clinically relevant outcome,
effect magnitude and number needed to treat);
c. applicability;
d. comparison with alternative interventions, including
doing nothing;
e. use of resources;
f. cost;
g. compliance, preferences, willingness to pay (WTP),
patient value.
Atopic dermatitis is not attributable to food allergy, ex-
cept in a small percentage of cases. For this reason,
evidence-based medicine (EBM) GL have not recom-
mended hydrolysed formulas, either for therapy or pre-
vention. The use of PHF in the prevention of AD has also
been the subject of a “qualified health claim”, a reasoned
recommendation from the analysis of scientific evidence
of the US Food and Drug Administration (FDA) [78]. The
FDA concludes that the evidence in support of a prevent-
ive effect of pHF on the development DA in children from
0 to 3 years is very limited. The FDA has issued a state-
ment as a warning to consumers, explaining that pHF are
hypoallergenic and should not be administered to children
with CMPA because of the risk of serious adverse reac-
tions. This warning statement was considered necessary
because the correlation between the use of PHF and a
lower risk of developing allergies can mistakenly cause the
public to consider these foods appropriate for allergic
children.
The most recent GL on rhinitis and asthma and pre-
ventive allergy do not include the use of hydrolysed for-
mula among preventive measures and recommend only
breastfeeding [70–73]. The evaluation of the efficacy and
safety of these preventive interventions do not justify the
recommendation.
Recommendation. A careful analysis of the evidence
and a cost/benefit valuation do not currently warrant
to characterise partially and extensively hydrolysed
formulas as safe an effective for the prevention of
allergic disease.
Appendix
Analysis of the evidence
Overall preventive effect on allergy
In the meta-analysis of seven studies by Osborn et al.
in 2009, a total of 2558 children were included [75]. The
RR of treatment is 0.79 [0.66–0.94] and the NNT is 12
[8–20], which means that 12 children on average (within
a 8–20 range) should be treated for one to benefit from
an effective prevention of allergy.
The meta-analysis by Szajewska and colleagues pro-
vides RR incidence and prevalence data for children fed
pHF. It includes three studies involving a total of 1281
patients (Vandenplas 1995, Chan 2003 GINI 200819)
and stratify the results by age (0–12 months, 0–36
months, 0–5/6 years) [76]. Intention To Treat analyses
(ITT) do not show statistically significant (SS) differ-
ences in the incidence of allergy among PHF and CMF
formula-fed subjects.
Preventive effect on food allergy
Osborn et al.’s meta-analysis examined only one study
dealing with the effect of hydrolysed formula in 141 chil-
dren at risk and reports an increased risk of developing
FA in children treated, in contrast to controls. One study
involving 67 children at risk shows a preventive effect
on CMPA (RR = 0.36 [0.15–0.89], and calculates a NNT
of 4 [2–17]). The systematic review by De Silva and co-
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workers reported two studies arguing against interven-
tion [77]. In two revised meta-analyses (Osborn and Sza-
jewska) and four studies, some of which were already
included in systematic reviews (GINI 2008 Vandenplas
1992 Chirico 1997 D'Agata 1996) showed a preventive
effect of intervention with pHF.
A preventive effectiveness of eHF is reported by two
systematic reviews (van Odijk 2003, Hays, 2005), with
two studies (Halken 1993 and 2000, Oldaeus 1997) in
favour, and one study against the use of eHF (Mallet
1992). Van Odijk and Hays revised reports are not up-
dated in the bibliography and include studies excluded
from subsequent revisions because of bias of various
types (non-randomised studies, excessive loss to follow-
up, surrogate outcomes, comparisons with soy formu-
las, etc.).
Preventive effect on allergic rhinitis and asthma
Only Osborn’s systematic review shows an effect on
rhinitis and asthma, and includes six studies of 1268 chil-
dren for asthma and 4 studies of 334 children for rhinitis.
Results, stratified by age: preschool asthma preschool age
and age were not statistically significant).
Preventive effect on atopic dermatitis
The meta-analysis of by Osborn and colleagues found
a preventive effect on atopic dermatitis in five studies and
three studies not in support of preventive intervention
among a population of 2558 patients, 1928 of whom had
been included in the GINI study in 2003.
The results, stratified by age are the following:
Preschool age: not statistically significant (NSS)
School age (incidence) NSS
School age (prevalence) NSS
In Szajewska’s meta-analysis only 3 studies could be
included in support of intervention among 1281 chil-
dren, 1113 of whom had been enrolled in the GINI
study in 2008 [81]. The results of the ITT analysis, strati-
fied by age are:
0–12 months: RR = 0.58 [0.32–1.04]; NNT = 22 (12–99)
0–36 months: RR = 0.71 [0.58–0.88]; NNT = 13 (8–33)
0–5, 6 years: RR = 0.80 [0.67–0.97]; NNT = 17 (9–119)
The reported results should be evaluated against the
methodological validity of the studies. Studies included
in reviews and meta-analyses may not only have been
intended to define preventive efficacy and safety but also
to comparatively evaluate different types of formulas,
and can include children at risk and not at risk and dif-
ferent lengths of supplementation. Generally, studies of
the use of partially hydrolysed and extensively hydro-
lysed formulas have low methodological quality in re-
spect of one or more of the following factors: incorrect
randomisation, low sample size, over 20 % loss to
follow-up, surrogate outcomes or clinically relevant diag-
nosis (e.g., sensitisation, atopic dermatitis) unconfirmed
by gold-standard tests (e.g., OFC for FA).
In the MACS study, included in De Silva’s review for
the evaluation of the effectiveness of soy milk, the re-
sults did not support a preventive effect of hydrolysed
formula, but cases of atopic disease were detected by
telephone survey and not directly confirmed by the au-
thors [81]. As for the comparison between pHF/eHF and
CMF and the few randomised studies with clinically
relevant outcome (including a diagnosis of FA confirmed
with OPT) and conducted on children at risk show con-
flicting results.
The results of two of the three systematic reviews con-
ducted by methodologically sound criteria (AMSTAR
score = 9.11) are contrasting [75, 77]. Some studies in-
cluded among those “in favour” of the preventive effect,
actually reported:
– Clinically irrelevant results (Chirico 1997 only on
immunogenicity and allergenicity);
– Or irrelevant (Halken 1993 2000: comparison of
efficacy and safety between PHF and eHF);
– Or no statistically significant difference between the
group fed hydrolysed formula and the control group
(GINI 2003, Oldaeus 1997).
One study showed a lower risk of developing, spe-
cifically, to the proteins in cow’s milk allergy (CMA),
NNT = 4, but that was conducted on only 67 children
(Vandenplas 1992).
The overall incidence of allergic diseases did not show
a preventive effect, either in early childhood or in later
life. Specifically, the study results are very inaccurate
estimates with wide confidence intervals in order to
demonstrate a preventive effect on the incidence of
atopic dermatitis, both in early childhood [NNT = 27
(15–135)], and in later life [NNT = 23 (11–150)].
Few studies of rhinitis and asthma showed, on average,
a preventive effect. The results should be considered
cautiously because the small sample size and the impre-
cision of the estimates.
The most recent studies not included in the revi-
sions analysed the results of the 7-, 10- and 15-year
follow-up to the GINI study (published in 2016) the
findings of which are based on self-reported diagnoses
obtained by a questionnaire, or spirometric parame-
ters non validated for the diagnosis of asthma, from a
loss to follow-up well above 20 % (35.5 %): the evalu-
ation must therefore take into account these meth-
odological limitations [82, 83].
ITT analysis shows that cumulative impacts are signifi-
cantly reduced only in the group that was fed eHF-C,
di Mauro et al. World Allergy Organization Journal  (2016) 9:28 Page 8 of 27
but this effect is mainly due to the incidence of AD and
the NNT is 11 [69–96]. The differences observed in the
prevalence of allergic manifestations are not, however,
statistically significant.
The methodological errors of studies with higher
sample size are likely to induce a lively discussion
about the validity of these results in the scientific
community [83–85].
Functional foods
Question 5. Is the use of functional foods (vs. no
intervention) recommended for the prevention of
allergic disease in children at risk of allergy?
Introduction
Fatty acids are the constituent ingredients of almost all
complex lipids in animal and vegetable fats. The absence
or presence of double bonds allows distinguishing satu-
rated from (mono- and poly-) unsaturated fatty acids.
Saturated and monounsaturated fats are mainly needed
for energy requirements, while polyunsaturated fatty
acids (PUFA) and long chain polyunsaturated deriva-
tives, with 20 or more carbon atoms (LCPUFA or LCP)
play structural and metabolic functions. PUFA α-
linolenic acid (ALA, C18: 3 ω-3) and linoleic acid (LA,
C18: 2 ω-6) are nutritionally important and are called es-
sential because the body cannot synthesise them and
they must therefore be introduced preformed in food.
The increased prevalence of atopic disease in industrial-
ized countries in recent decades has been attributed to
changes in nutritional habits and, in particular, to fat
consumption. According to this hypothesis, the in-
creased intake of linoleic acid, with the consequent in-
crease in the synthesis of arachidonic acid, would lead to
increased formation of PGE2, of which arachidonic acid
is a precursor. PGE2 is a potent activator of Th2 lym-
phocytes and leads to a reduction in IFNγ levels and an
increase in IL-4. These changes stimulate a B lympho-
cytes response with the production of IgE which may de-
termine predisposition to allergic sensitisation. Increased
intakes of ω-3 in the diet have been associated with a de-
crease in the pro-inflammatory effects of arachidonic
acid at several levels, reducing the production of eicosa-
noids and a Th2 response.
Methodological note
The search strategy is shown in the relevant section.
The evaluation of the scientific evidence is made explicit
in the text.
The population likely to benefit from preventive inter-
ventions includes: pregnant women and lactating mothers
of children with a first-degree blood relative of who suffers
from atopy, children at risk of allergy, according to the
definition provided, taking functional foods as supple-
ments. The latest updates of evidence-based studies, as
well as of research and evaluation of evidence, are de-
scribed in the Appendix.
Previous recommendations. NIAID EAACI 2010 and
2013 guidelines (food allergies), BTS/SIGN and GINA
2012 (asthma), AIR 2013 (rhinitis) and SIGN 2011
(atopic dermatitis) do not recommend the supplementa-
tion of ω-3 among preventive measures because of in-
consistent results in the studies so far conducted.
Analysis of the evidence
A systematic review (SR) published in 2014 and
three subsequent studies at the closing date of the lit-
erature search of the SR was included [87–89]. De
Silva’s SR includes Anandan 2009 SR and shows a
prevention effect and an increased risk of developing
asthma, rhinitis and atopic dermatitis [88] for ω-3
and ω-6 supplementation. No preventive effect of
polyunsaturated fatty acids on the development of
food allergies and other atopic diseases has been
demonstrated, whether administered to children or
mothers during pregnancy or breastfeeding [76, 85, 86].
Palmer and D'Vaz’s studies are randomised controlled
trials evaluating the effectiveness of the preventive ad-
ministration of fish oil, respectively in pregnant
women (from week 21 to delivery) and children at
risk. They include some serious methodological errors
(such as unconfirmed diagnosis using a gold-standard
test, duration of follow-up limited to the first
12 months of life, loss to follow-up > 20 % (in D'Vaz’s
study) [87–89]. The results did not find statistically
significant differences between the treatment group
and controls. Numerous studies have also evaluated
the intake of vitamins (Vit A, E, C) and minerals
(Mg, Zn, Ca, P) [please note that except for this
chapter the data on vitamin D is treated in a special
section], but these often include methodological er-
rors, starting with the difficulty of finding a correct
quantification of dietary intakes of various foods. This
makes assessing a possible relationship with allergic
disease development difficult.
The results of these studies, even for the foods they
investigate, are contradictory.
West et al. evaluate the effect of the administration of
antioxidants (β-carotene, vitamin C, vitamin E, copper
and zinc) on the development of allergic disease in chil-
dren [93]. Their results demonstrate a protective effect
of vitamin C on the incidence of wheezing and a pre-
ventive effect of the contribution of copper on the devel-
opment of various allergic diseases. However these
results cannot be used because this study has important
methodological flaws.
Recommendation. No preventive effect on the de-
velopment of allergic disease of the supplementation
of ω3 polyunsaturated fatty acids, vitamins or min-
erals has been demonstrated when administered to
children and/or their mother during pregnancy or
breastfeeding.
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Box 3: Essential fatty acids
Early community exposure
Question 6. Should early community exposure
(under 24 months of age) be recommended or not
recommended for the prevention of allergic disease?
Introduction
The hygiene hypothesis
In the late 1980s, the so-called hygiene hypothesis was
formulated in order to explain the increased prevalence of
allergic diseases observed in many epidemiological studies.
This hypothesis assumed a causal association between the
reduced frequency of infections and the increase in aller-
gic disease, as a consequence of improved hygienic condi-
tions, antibiotic prophylaxis and the widespread use of
vaccination. A first important paper in support of this hy-
pothesis in 1989 was written by David Strachan who had
observed an inverse relationship between the number of
siblings, birth order and hay fever in a large British cohort
[97]. The immune system of children, leading a “Western”
lifestyle were predominantly directed towards an allergic-
type response because they did not contribute to defence
against infectious agents and thus induced the maturation
of a mainly T-helper type 2 (Th2) rather than T-helper
type 1 (Th1) immune response. Indeed, the imbalance of
T helper lymphocyte response to common environmental
antigens plays a key role in the pathogenesis of atopic
diseases in genetically predisposed individuals.
Box 4: The “classical” Th1/Th2 dichotomy and the
Th17 line.
Other evidence for the hygiene hypothesis consisted in
the observation of a reduced rate of allergies among
children living in countries with low sanitary conditions
and lower health education (associated with an increased
incidence among immigrants from these countries in the
West) or amid children who have contracted tubercu-
losis or measles, of an inverse correlation between risk
of developing allergy and family educational level, as well
as vaccination for measles or conditions conducive to in-
fections, such as a large number of siblings and early age
at first exposure to community contacts [97].
State of knowledge
Early community exposure as a protection factor in
allergy development.
Early observational studies dating back to the 1990s
have reported conflicting results about early exposure to
the community, which lay children open to an increased
risk of infections in their first year of life [100–104].
Among these, a large study including over 2000 children
was conducted in Germany by Kramer et al. showing
that day-care attendance between 6 and 11 months and
between 12 and 24 months could be a protective factor
in the later development of asthma, allergic rhinitis and
skin sensitisation, limitatively to the subgroup of chil-
dren without sibling [105].
Outcome variability from study to study as well as dif-
ferent definitions of wheezing and asthma make inter-
preting the data difficult. The European Respiratory
Society definitions of asthma and wheezing are reported
The classic paradigm of the Th1/Th2 dichotomy has been made
obsolete by the discovery of other cell lines. There are CD4 + T-helper
cells expressing interleukin 17 (IL-17) and numerous categories of
regulatory T cells (Treg) able to control effector T-cell responses have
been described. While, strictly speaking, Tregs cells originate directly
from thymic precursors, inducible Treg cells (iTreg) cells and Tr1 cells
Th3 differ from precursors of peripheral T-helper cells through the
action of several cytokines such as TG F-β, IL-2 and retinoic acid (Fig. 1).
Th17 cells play a role in the immune response to self and, along the
two “classic” Th1 and Th2 cell lines and Treg, represent not only a key
component of the innate immune response to infection, but also exert
a pro-inflammatory effect and promote tissue damage in various
chronic inflammatory diseases such as asthma [98]. Recent studies have
confirmed a role of this cell line in the pathogenesis of asthma in
children of school age [98, 99].
Essential fatty acids are precursors of LCP, the synthesis of which is
achieved through sequential enzymatic reactions of chain elongation
(elongase) and desaturation (desaturase). The enzymes involved in the
reactions of elongation and desaturation of these fatty acids are
common to the two biosynthetic pathways (ω-3 and ω-6 series) and
display a “competing for substrate” mechanism (Fig. 1). Eicosapentaenoic
acid (EPA, C20: 5 ω-3) and docosahexaenoic acid (DHA, C22: 6 ω-3) are
derived from acid α-linolenic acid and arachidonic acid (AA, C20: 4 ω-6).
is derived from linoleic acid. Eicosapentaenoic acid (ω-3), docosahexaenoic
acid (ω-3) and arachidonic acid (ω-6) have particular biological significance
as fundamental components of cell membranes (especially in the brain
and retina). They are precursors of eicosanoids, compounds which consist
of 20 carbon atoms (from the Greek éikosi), and are highly bioactive,
acting as intercellular mediators and/or locally-acting and controlling
hormones. Arachidonic acid it is the predominant precursor, present in
high concentrations in all membrane phospholipids. Three different
enzyme systems oxidize AA: cyclooxygenase (with training prostaglandins
and thromboxanes), lipoxygenase (with the production of leukotrienes)
and cytochrome P450 monooxygenase (forming 19- and 20-HETE). The
biological activities of eicosanoids are varied: for example, prostaglandin
E2 (PGE2) acts on blood vessels, airways, the stomach, the kidneys,
neutrophil function, lymphocytes and pain receptors. Even ω-3 fatty acids
can be used for the synthesis of eicosanoids, which, however, have
opposed characteristics from AA-derived eicosanoids, determining
smooth muscle relaxation and vasodilatation (prostacyclins). For this
reason, the mechanism of competition for substrate has a very precise
meaning: ω-6 fatty acids, in fact, are much more abundant in nature and
in the “Western” diet, but enzymatic chain processing favours ω-3 fatty
acids when present. Long-chain polyunsaturated fatty acids are best
known for their possible effects on the central nervous system as a
component of cell membranes, but they are also associated with the
modulation of immune responses as precursors of eicosanoids [90].
The “anti-inflammatory” effect of EPA and DHA (found in fish and, in
particular, their oils) is based on a competitive mechanism: at the
membrane level, these LCPUFA of the ω-3 series replace AA (from
which highly inflammatory eicosanoids are derived) and determines
decidedly bland inflammatory eicosanoid activities. The intake of
fish oil would, therefore, exert a potentially anti-inflammatory effect.
In contrast, the increased consumption of vegetable oils rich in ω-6
polyunsaturated fatty acids is one of the main dietary factors in the
allergic epidemic [93–95].
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in Box 5 and are considered for the purpose of this
Consensus [106]. Therefore, the results of studies using
different definitions have been critically evaluated.
Box 5: Definition of wheezing according to the
definitions of the European Respiratory Society [107]
Wheezing is common in preschool children. Popula-
tion studies have shown that about a third of children in
their first 3 years of life develop at least one episode of
wheezing which reaches a 50 % prevalence within 6
years. Wheezing is the main clinical expression of
asthma and is a sign not specifically caused by the pas-
sage of air through constricted airways.
This phenomenon is often transient and resolves in
most cases early, between 3 and 6 years of age, or some-
times later in childhood, between the 11th and 13th
year. In a group of patients, it tends to persist into adult-
hood, and associates with allergic sensitisation and
asthma.
Ball and colleagues evaluated the incidence of asthma
(defined as the presence of at least one episode of
asthma diagnosed by a physician between 6 and 13 years
of age) and the prevalence of recurrent wheezing (de-
fined by the presence of more than 3 episodes of wheez-
ing in the previous year) in relation to the number of
siblings living together and early community exposure in
a large cohort of 1035 American children followed from
birth. The presence of one or more older siblings living
together resulted protective against the subsequent de-
velopment of asthma (adjusted relative risk [aRR] for
each brother: 0.8; 95 % CI: 0.7–1.0; p = 0, 04), as well as
entry in the community during the first 6 months of life
(aRR: 0.4; 95 % CI: 0.2–1.0; p = 0.04). Children with
greater exposure to other children, at home or in day
care had a higher probability of recurrent wheezing at
the age of two than children without siblings or those
who were not exposed early to community influences
(aRR: 1.4; 95 % CI: 1,1–1.8; p = 0.01). These children
ran a lower risk of asthma at 6 (aRR: 0.8; 95 % CI:
0.6–1.0; p = 0.03) and 13 years (aRR: 0, 3; 95 % CI:
0.2–0.5; p <0.001). However, the definitions of asthma
and wheezing adopted by this last study are not those of
the present Consensus. This study was also later criticized
because early community exposure not only determines
a greater frequency of infections but also exposes the
child to other potential risk factors for asthma [108].
Other authors analysed the results by distinguishing be-
tween the different phenotypes of wheezing in accordance
with the definitions of the European Respiratory Society
as reported in this Consensus (Box 5). The study by Cau-
dri and colleagues, for example, included more than 2700
children followed from 3 months to 8 years of life [109].
Risk factors significantly associated with transient wheez-
ing were male gender, positive maternal and paternal fam-
ily history of allergy, lower maternal age at delivery, high
maternal body mass index, premature birth, maternal
smoking during pregnancy, presence of older live-in sib-
lings and day care attendance. Male gender, family history
of allergy (maternal or paternal), no breastfeeding or last-
ing less than 12 weeks were identified as risk factors for
persistent wheezing in this population.
Day care attendance was associated with transient
wheezing, and most likely, but not certainly, may be as-
sociated with allergic asthma, also in accordance with
the criteria of the modified Asthma Predictive Index
(Box 6) [107, 110]. The interpretation of the results is
affected by the outcomes analysed (risk factors for tran-
sient or persistent wheezing and allergic asthma, the
subject of this Consensus).
Finally, infants with older siblings, those who attended
childcare by 6 months of age and those with dogs at
home were less likely to develop food allergy (adjusted
OR [aOR] 0.7, 95 % CI 0.5, 0.8, aOR 0.5, 95 % CI 0.3, 0.8
and aOR 0.6, 95 % CI 0.5, 0.8, respectively), but these
results need to be confirmed.
Box 6: Risk factors for the development of asthma
(modified Asthma Predictive Index or API) for children
with wheezing (modified from reference [110]).
Temporal pattern of wheezing
Episodic (viral) Wheezing during discrete periods of time, often in
association with clinical evidence of viral cold, in the
absence of wheezing in the inter-critical periods
Multiple-trigger Wheezing with exacerbations over time, but also
symptoms during periods between one episode
and the other
Duration of wheezing
Transitory Symptoms that begin before 3 years and disappeared
(retrospectively) within 6 years; wheezing transition
can be either episodic or multiple-triggered
Persistent Symptoms that persisted (retrospectively) over 6 years;
persistent wheezing can be either episodic or
multiple-triggered
Late-onset Symptoms begin after 3 years of age; either episodic
or multiple-triggered
≥4 episodes wheezing last
year associated with:
One major criterion:
•One parent with asthma
•Atopic dermatitis
•Sensitisation to inhalant allergen
or
Two minor criteria:
•Sensitisation to foods
•Wheezing outside of infective episode
•Eosinophilia (>4 %)
A positive API index is associated with an increased probability of
developing asthma between 6 and 13 years from 4- to 10-fold. More
than 95 % of children with negative API score in the first 3 years of life
do not develop asthma between 6 and 13 years.
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Over the years, it seems that the consensus on the hy-
giene hypothesis has declined. A protective effect in al-
lergy has been suggested for some respiratory viruses,
measles, hepatitis A and tuberculosis although extensive
and rigorous studies have not borne it out [110]. Other
studies have reported that anti-tuberculosis, diphtheria,
pertussis and measles vaccination exerted no protective
effect on the development of allergic diseases before
school age [111]. Some recent data have demonstrated
that there was no association between the prevalence of
infection in children, prevalence of infection among
siblings or the use of antibiotics and the development of
allergy after 2 years of life. In a Swedish study by
Hagerhed-Engman and co-workers of 10,000 children, it
was shown that day care attendance was not a protective
factor in the development of allergy at the age of 6 years
[112]. A recent systematic review by Marrs et al. could
identify only a single high- quality study that investi-
gated the association between early introduction in the
community and food allergy [112, 113]. This study re-
ported that children introduced into community expos-
ure within the first 6 months of their life ran a
significantly higher risk of sensitisation to egg, sesame
and peanuts (aOR 0.5; 95 % CI 0.3–0.8) compared with
children who did not attend day care [113].
Early community exposure as risk factor for the devel-
opment of allergies
In contrast to the hygiene hypothesis, some studies
have demonstrated that infections may instead promote
the development of allergies, rather than reduce their
risk. An association between viral infection (rhinovirus
and respiratory syncytial virus [RSV], primarily) in early
infancy and subsequent risk of asthma has in fact been
reported among children at high risk [114, 115]. How-
ever, the exact role of RSV remains controversial in this
setting [116]. Respiratory infections, particularly infec-
tions caused by viruses, and day care attendance could
therefore constitute risk rather than protective factors
for the manifestation of an atopic phenotype. The asso-
ciation between respiratory infections contracted at an
early age and the development of allergic asthma in later
periods is not yet clear, nor is whether it is secondary to
the fact that children predisposed to develop allergy have
a dysregulated immune system and an increased suscep-
tibility to infection [117]. A possible association between
the development of allergy and the use of antibiotics and
antipyretics is also reported. However, this association
may be an indirect marker of infection rather than a
consequence of the direct action of these drugs [107].
A cross-sectional survey of a large Finnish population
by Paunio et al., observed a higher association between
measles in children and the subsequent development of
allergic diseases [114]. Further, infants who spend their
first night of life in the nursery have a higher risk of
developing allergy than those who sleep in contact with
their mother [115]. A study of over 3000 children in day
care conducted in Germany by Cramer and colleagues
showed day care attendance is the only risk factor from
among 11 possible factors analysed for the development
of atopic dermatitis within 2 years (OR: 1.56; 95 % CI:
1.31–1.86). The authors concluded that other environ-
mental factors, not included in the hygiene hypothesis
could account for this result [116].
Conclusion
The discussion about the validity of the hygiene hy-
pothesis is ongoing but data from the literature and ex-
pert opinions are mixed. Early entry of a child in the
community cannot currently be safely demonstrated to
prevent the development of allergic disease. In contrast,
some non-conclusive data suggest that infections can
promote the development of allergies in children at high
risk of atopy. However, further studies are needed to
clarify whether this association is real or does not indi-
cate a higher susceptibility to infections among allergic
children.
Introduction
The literature data do not support the hygiene hy-
pothesis (according to which early community expos-
ure would protect from the subsequent development
of allergies as a result of infections).
Recommendation. Early community exposure is not
recommended to prevent the development of allergy
Introduction
Other authors, however, have suggested that early
community exposure may be associated with subse-
quent development of allergies because viral infec-
tions contracted in the first 2 years of life could
cause immune and structural changes in the respira-
tory tract. The evidence from the literature, however,
remains controversial and therefore, does not support
definite conclusions. This association could only re-
flect a higher predisposition of allergic children to
infections.
Recommendation Early entry into the community
cannot be considered a risk factor for the develop-
ment of allergy.
Vitamin D
The purpose of this document is to consider the
administration of vitamin D for the primary preven-
tion of allergies on the basis of the available scientific
evidence. The targets of this analysis are paediatri-
cians, patients’ families and all health professionals in-
terested in allergy prevention in children.
Introduction
The prevalence of allergic diseases in children is af-
fected by family history and ranges from 10 % among
children with negative history to up to 20–30 % in
the presence of a first-degree allergic relative [118].
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In recent years a possible role in prevention has been
attributed to vitamin D. Indeed, observational and co-
hort studies have documented the existence of a correl-
ation between vitamin D intake (from dietary sources or
supplementation) in pregnant women and children and
the risk of wheezing, asthma or food allergy later in life.
In the literature, epidemiological studies show that the
incidence of allergic diseases also increases with
increasing latitude and in consequence of decreased
exposure to sunlight.
Notes on vitamin D metabolism
Exposure to sunlight is the main source of vitamin D:
ultraviolet B rays induce the production of cholecalcif-
erol (vitamin D3) in the skin, and it is then hydroxylated
to 25-hydroxyvitamin D3 (25 [OH] D) in the liver. PTH
then regulates the hydroxylation of 25 [OH] D to its
biologically active form (1,25[OH]2D3) in the kidney.
1,25[OH]2D3 is activated by binding to the vitamin D
receptor and with subsequent regulation of gene ex-
pression. Other sources of vitamin D are foods, espe-
cially fatty fish and dairy products, and administered
supplements.
There is currently no common definition of the
threshold below which vitamin D deficiency begins.
While a 20 ng/mL threshold is generally agreed upon
for musculoskeletal pathology to develop, discriminat-
ing thresholds for other health effects have not been
defined. However, several studies report suboptimal
vitamin D status in large parts of the population of
children and adults. In Italy, recent studies have
documented vitamin D levels below 20 ng/mL in
32 % of children of normal weight and in 44 % of
obese children [119]. Low levels of vitamin D have
been detected in up to 40 % of adolescents in one
study population [120].
State of knowledge
A recent meta-analysis investigated the relationship
between alterations of vitamin D status and a number of
pathological conditions [121]. Historically, vitamin D has
been associated with musculoskeletal diseases such as
rachitism, osteoporosis, fractures and muscle weakness.
In the last 15 years, other conditions such as cancer
as well as cardiovascular, metabolic, infectious, auto-
immune and allergic diseases have all been linked to
rachitism.
The results of this meta-analysis supports a correlation
between low vitamin D status and diseases such as
hypertension, rachitism in children, vaginosis in preg-
nancy, the level of activity of rheumatoid arthritis, colo-
rectal cancer and falls in the elderly. However, no
conclusive evidence was found for 70 other conditions
assessed.
We performed an additional search of the literature
using the search strategy reported in the Appendix.
The following possible outcomes of intervention
were considered:
 Atopic dermatitis
 Allergic rhinitis
 Asthma
 Food Allergy
 Allergy (any)
Question 7. Is the administration of vitamin D
recommended during pregnancy to prevent allergic
diseases in children?
Question 8. Is the administration of vitamin D in
doses higher than recommended intakes for the first
year of life recommended for the prevention of aller-
gic diseases?
Question 9. Is the administration of vitamin D in
doses compliant with recommended intakes sug-
gested for the first year of life recommended for the
prevention of allergic disease?
In 2012, Paul et al. evaluated 10 observational studies
(including 7 neonatal cohorts) on the maternal action of
vitamin D in the diet or serum levels and asthma [122].
The study conclusions were that there was not sufficient
evidence to establish a causal connection; there were
also no randomised clinical trial (RCT) on the effect of
supplementation of vitamin D and risk of asthma. Other
observational studies, including two neonatal cohorts,
were subsequently published [123, 124]. Overall, 6 co-
horts of newborns enrolled more than 750 infants. One
showed no correlation and the other 5 found an inverse
relationship between vitamin D intake (through diet or
supplementation) or vitamin D levels in umbilical cord
blood and the incidence of asthma or wheezing at 1–3
or 5 years of age. All these cohorts suffer from a patient
dropout rate varying between 24 and 52 % and are
therefore at risk of substantial bias. In the cohort studied
by Rothers and colleagues, high and low vitamin D levels
are associated with an increased risk of sensitisation
[123]. In 2013, a randomised, controlled study by Goldr-
ing and co-workers studied 113 children receiving pre-
natal supplementation of vitamin D. No effect on atopy,
risk of atopic dermatitis, pulmonary function and
exhaled nitric oxide was found [125].
Despite a thorough analysis of the literature, in 2013
Peroni et al. published an exhaustive review concluding
that there were no conclusive data identifying a possible
dose of vitamin D resulting in prevention of food
allergy [126].
In particular, in addition to studies showing an inverse
relationship between vitamin D and atopic dermatitis,
studies report that high vitamin D levels in umbilical
cord blood determines a higher risk of allergic sensitisa-
tion and food allergy [127, 128].
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The relationship between vitamin D and prevention of
allergic diseases is strong when epidemiological and
ecological studies are considered. The results remain
controversial even when correlations between vitamin D
levels in maternal and umbilical cord blood and allergic
disease risk are measured directly. Of note, the then only
available RCT (Goldring) did not show any such
correlation.
Conclusions
Although the available literature data suggest the
existence of a relationship between latitude and its
consequent degree of ultraviolet radiation exposure,
vitamin D levels and the prevalence and severity of
allergic diseases, the data of observational studies are
encouraging, but controversial and the only available
RCT fails to show an effect on allergic disease
prevalence.
The use of vitamin D supplementation for the primary
prevention of allergic diseases remains an attractive
topic of study, but current knowledge and available
evidence does not warrant its recommendation [129].
Several randomised controlled trials are underway and
they will certainly inform future recommendations on
the basis of more solid evidence.
Recommendation. On basis of the available evi-
dence, the use of vitamin D supplementation is not
recommended for the primary prevention of allergic
disease.
Probiotics and prebiotics
Question 10. Should probiotics or prebiotics be
administered to women during pregnancy for the
purpose of prevention of allergic disease in their
children?
Question 11. Should probiotics or prebiotics be ad-
ministered to women during breastfeeding for the
purpose of prevention of allergic disease in their
children?
Question 12. Should probiotics or prebiotics be
given to (exclusively and otherwise) breastfed infants
for the purpose of preventing allergic disease?
Introduction
This aim of this section is to consider the use of pro-
biotics and prebiotics for the primary prevention of
allergies on the basis of the available scientific evidence.
In recent years, alterations in the intestinal microbiota
have been considered as a factor for the modulating
of immune and inflammatory responses, and these
changes have been indicated as a possible cause of the
increase in the incidence of allergic diseases [130, 131].
This is a consequence of the theoretical concept that
changes in the opposite direction may be able to re-
duce the risk of developing allergic disease. These
considerations are the basis of the hygiene hypothesis
as exposed below.
The hygiene hypothesis
The immune system at birth has some knowledge of
the self, but little experience of the outside world, and
what it has been transferred through the placenta from
the mother.
After birth, the development of the immune system
necessitates contact with microorganisms, so that it can
properly develop some basic functions: among them, the
acquisition of specific memory for molecular patterns
which later accelerate the subsequent recognition of
potential pathogens, the maintenance of a level activation
of innate immunity and the support of the development of
regulatory mechanisms that block, via a Treg-mediated
response, the onset of autoimmune and allergic diseases.
The incidence of autoimmune and allergic diseases in-
creases if this mechanism is lacking. Interactions with
numerous micro-organisms such as fungi, bacteria,
protozoa, helminths and bacteria of the human micro-
biota (in the intestine, on the skin or in the respiratory
and urogenital tracts) have been incorporated in the
genesis and maintenance of mechanisms of immune
regulation. An evolutionary concept of the hygiene hy-
pothesis has then been developed. This concept focuses
on lifestyle changes that can reduce overall exposure
(and therefore beneficial interactions) between the im-
mune system and these immune regulatory agents. In
particular, because of this western lifestyle many of these
exposures are increasingly reduced (agricultural methods
resulting in low biodiversity in food crops, reduced ex-
posure to ecto- and endo-parasites, reduced prevalence
of chronic infections) [132]. In this context, therefore,
we are particularly dependent on our human microbiota
which this has an important role to play as an immuno-
regulatory factor. Even so, the microbiota undergoes a
process of quantitative and qualitative reduction. In
many studies, this process is associated with an in-
creased incidence of allergic and autoimmune diseases,
which result from a lower efficiency of the regulatory
functions exercised by the immune system. The experi-
mental model of supplementation with prebiotics and/or
probiotics is based on these findings. This model aims
towards inducing and maintaining a high bacterial load
and a qualitative richness of the gut microbiome to sub-
sequently correct the effect of reduced exposure linked
to lifestyle.
Probiotics
Probiotics are ubiquitous in the daily diet of all
humans. This document considers the administration
of probiotics as supplements but it does not consider
the exposure that occurs with common food intakes
that may naturally contain probiotics (yogurt, fermen-
ted milk and the like). From a methodological point
of view, the following populations are considered for
possible intervention with probiotics: pregnant women,
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breastfeeding mothers, infants exclusively and not ex-
clusively breastfed.
All types of probiotics and doses thereof were consid-
ered. Studies in which probiotics were used for prevent-
ive purposes were evaluated.
The following possible outcomes of intervention were
considered:
 Dermatitis
 Allergic rhinitis
 Asthma
 Food Allergy
 Allergy (any)
 Adverse events
 Nutritional status
Results
In this consensus, we considered the results of a meta-
analysis in the literature and we integrated it with the
consultation of the literature and EAACI guidelines on
the primary prevention of food allergy [133].
Analysis of knowledge
Previous recommendations. We first searched in
literature for the presence of recommendations on each
question.
Question 10
The recommendations for supplementation in preg-
nant women are poor: the guideline of the Finnish
Medical Society recommended the administration of
probiotics for primary prevention of allergies but only 2
studies (included in the subsequent metanalysis) were
considered. The NIAID guidelines do not make specific
recommendations. The 2006 NASPGHAN Report and
the 2007 and 2011 Cochrane Database reviews do not
provide guidance and report uncertain evidence (paedi-
atric studies only) [134, 135].
Question 11
The recommendations for the supplementation of
mothers during breastfeeding are poor: the Finnish Med-
ical Society guidelines do not recommend the adminis-
tration of probiotics for the primary prevention of
allergy in mothers during lactation, but only two studies
(included in the subsequent metanalysis) are considered.
The NIAID guidelines do not make specific recommen-
dations. The 2006 NASPGHAN Report and the 2007
and 2011 Cochrane Database reviews do not provide in-
dication and report uncertain evidence (paediatric stud-
ies only) [134, 135].
Question 12
The recommendations in favour of supplementation
are poor: the guidelines of the Finnish Medical Society
recommend administering probiotics for primary pre-
vention of allergy, but only 2 studies (included in the
subsequent metanalysis) are considered. The NIAID
guidelines do not make specific recommendations. The
2006 NASPGHAN Report assigns a level-I evidence
rating and the 2007 and 2011 Cochrane reviews do not
provide indication and report uncertain evidence (paedi-
atric studies only) [134, 135].
Question 10
We evaluated 8 systematic reviews on this question
published between 2007 and 2013. Their main targets
are atopic dermatitis (five studies), asthma/wheezing
(two) and safety (one).
Atopic dermatitis
The meta-analysis by Lee et al. analysed data from
1581 patients for pre- and post-natal administration
and shows a preventive effect with a RR of 0.69 (CI:
0.57–0.83) [136]. Betsi and colleagues analysed the
data of 4 studies [136]. Three studies (584 patients)
reported a significant reduction in the incidence of
dermatitis and one study (89 patients) did not detect
any preventive effect. Doege and co-workers’ meta-
analysis also documented a modest preventive effect
(RR: 0.82, CI: 0.71–0.95; 2843 patients) through the ad-
ministration of Lactobacilli, but this did not into a
similar an effect when mixtures of probiotics were used
[137, 138]. Lint et al. reported data extracted from a
meta-analysis of 13 studies and found a significant pre-
ventive effect (RR: 0.79, CI: 0.71–0.88) [139]. A specific
subgroup analysis did not distinguish between specific
strains (a sub-analysis of six studies with Lactobacillus
rhamnosus GG showed comparable efficacy) nor for
routes of administration (pregnant mother, mother/
nursling or child). In Foolad and colleagues’ systematic
review of 9 of 10 studies, a reduced risk of atopic
dermatitis was reported with estimated efficacy varying
from 30 to 70 % [140].
Other allergic diseases
Supplementation with probiotics was not protective
against food allergy, asthma or allergic rhinitis in either
metanalysis [141, 142].
Safety
Dugoua et al.’s meta-analysis failed to detect any ma-
ternal side effect following administration of Lactobacilli
and Bifidobacteria [143].
An assessment of adverse effects across all age groups
considered 622 studies. Only in 387 studies were adverse
events adequately reported and differences in gastrointes-
tinal symptoms (RR 1.00 [0.93–1.07]), infections or other
adverse events (RR 1.06 [0.97–1.16]) associated with the
use of probiotics were not detected. Adverse events
with long-term supplementation remain unknown [144].
Question 11
No examined systematic review directly address this
question and thus the evidence needed to answer this
issue must be derived from the studies previously
described.
di Mauro et al. World Allergy Organization Journal  (2016) 9:28 Page 15 of 27
Question 12
The method of administration (for children only) was
evaluated by some revised versions of the studies men-
tioned and in part already displayed [134–136, 142, 143,
145, 146]. Only Osborn’s meta-analysis detects an effect on
the prevention of atopic dermatitis, but heterogeneity
across studies makes the extent of such an effect uncertain.
In other reviews, no efficacy of probiotic supplementation
for the prevention of allergic disease has been observed.
In 2014, a systematic review once again confirmed the
ineffectiveness of supplementation with probiotics for
the prevention of food allergy. Experimental work con-
ducted in a population of 220 children showed a lack of
effect for the prevention of allergic disease [133].
Prebiotics
We considered the results of meta-analyses from the
literature, integrating them with the results of the con-
sultation of the most recent articles on this topic. The
rationale behind the use of prebiotics is based on the
modulation of the quantity and quality of the gut
microbiome, as explained in the introductory section.
The methodology, the questions and possible out-
comes of intervention were identical to questions
about probiotics.
Results
In 2013 a systematic review and 2 meta-analyses were
published on the subject of supplementation with prebi-
otics. The systematic review, carried out by Foolad and
co-workers, evaluated the effect of supplementation with
prebiotics on atopic dermatitis [140]. This systematic re-
view analysed the results of two studies for the preven-
tion of atopic dermatitis.
The first study reported a 50 % reduction in the cumu-
lative incidence of atopic dermatitis after 2 years in chil-
dren who were given a mixture of prebiotics in the first
6 months of life [147].
The second study demonstrated a reduction in the risk
of developing atopic dermatitis (HR 0.56, CI: 0.323–
0.971, NNT = 25 to prevent one case of dermatitis
among infants) in a group of infants fed with a formula
supplemented with a mixture of prebiotics [148].
Osborn’s meta-analysis does not show efficacy in the
prevention of asthma (2 studies, 226 children). Four
studies (1218 infants) are analysed for atopic dermatitis
and efficacy in reducing the risk of eczema is demon-
strated (RR 0.68, 95 % CI: 0.48–0.97; NNT 25) [149].
Subgroup analysis does not differentiate between chil-
dren for risk of disease. The authors comment that the
studies differ according to type of prebiotics used,
duration of administration (1–12 months) and length of
observation (4–24 months).
In Srinivasjois and colleagues’ meta-analysis the
complete safety of prebiotic supplementation is docu-
mented for premature infants [150].
In 2013 a further study of the protective effect of
prebiotics on allergic outcomes was published. In this
paper by Ivakhnenko et al. 80 infants were fed formula
supplemented with prebiotics and compared to breastfed
infants or infants fed with conventional formula. The in-
cidence of atopic dermatitis in the supplemented group
was significantly lower, but this paper suffers from meth-
odological problems, including the loss of more than
30 % of the enrolled population.
Conclusions
This comparative assessment of the literature shows a
modest efficacy of probiotics in the prevention of atopic
dermatitis when administered to the mother during
pregnancy and to the mother and baby during
breastfeeding
Favourable effects of the administration of probiotics
to breast- or formula-fed infants remain unclear when
probiotics were not supplemented pre- or post-natally to
their mothers.
No administration modality exerts a preventive effect
on asthma, rhinitis or prevents allergies. The safety pro-
file is excellent, and significant adverse events in the
treated groups were not found in any revised literature.
Supplementation of probiotics to prevent allergic
diseases cannot be recommended on the basis of the
available evidence. Encouraging data on a possible re-
duction in the risk of atopic dermatitis should be inter-
preted with great caution as 25 infants have to be
treated to prevent a single case of dermatitis and sev-
eral studies suffer from a high percentage of patients
lost to follow-up.
Recommendation: supplementation with probiotics
The administration of probiotics for the prevention
of asthma, rhinitis and food allergy cannot be recom-
mended as available studies demonstrated their inef-
fectiveness in the literature. The administration of
probiotics to the mother during pregnancy and/or
after delivery, and in together with their child during
the first 6 months of life, can be considered as an
intervention for the prevention of atopic dermatitis,
even in the infrequent cases in which the prevailing
trigger is food, among children at risk. The effect is
moderate but constant across studies available in the
literature.
Recommendation supplementation with prebiotics
At the state of knowledge no recommendations of
the use of prebiotics can be issued.
APPENDIX
For the purpose of this report, the following defini-
tions have been used:
Probiotics: live microorganisms that confer a health
benefit to the host when administered in adequate quan-
tity as part of the supply (FAO/WHO Expert Consult-
ation, 2001). Prebiotics: the definition of prebiotic is
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reserved for non-digestible substances in the diet that
selectively promote the growth and activity of one or
more bacteria already present in the intestinal tract, or
taken together with the prebiotic when consumed in
adequate quantity.
Foods/supplements with prebiotics are defined as
those foods that contain, in adequate quantity, prebiotic
molecules capable of promoting the development of
bacterial strains beneficial to humans.
Indoor allergens
Question 13. Should environmental prevention for
dust mites be recommended for children at risk of
allergic disease?
Introduction
Dust mites have been recognised as a major source of
indoor allergens since the 1960s; Dermatophagoides fari-
nae and Dermatophagoides pteronyssinus are the most
frequent species of house dust mites found in temperate
regions.
The mites feed on organic material, including flaking
skin cells, fungi, yeasts and bacteria. They are made up
of 75 % water and retain an optimal hydrostatic equilib-
rium in environmental conditions characterised by levels
of relative humidity equal to 65 %. The main factor that
affects mite growth is the degree of relative humidity; its
reduction to below 50 % results in a reduction in the
scale of their proliferation [151].
Mites release numerous allergens in the environment,
including cysteine protease (Der p 1, Der f 1), serine pro-
teases (Der p 3, 6 and 9), glycosidases, carbohydrate
binding proteins, calcium-binding proteins, muscle pro-
teins and cytoskeleton. Proteases, in particular, exert a
pro-inflammatory activity in humans (through a non-
IgE-mediated mechanism) while tropomyosin (Der p 10)
explains the existing cross-reactivity of these proteins
with others found among arthropods such as crusta-
ceans [152].
There is evidence to suggest that exposure to dust
mite allergens at levels above 2 mg/g is associated with a
very high risk of developing allergic sensitisation [153].
Exposure levels greater than 10 g/g would be associated
with exacerbated asthma in patients allergic to mites
[154]. The reduction in exposure to these allergens,
therefore, could reduce the severity of asthma and sup-
port the concept of prevention through environmental
control.
Summary of knowledge
Which are the main environmental sources of mites?
Mites develop inside the home in conditions charac-
terised by high levels of relative humidity which, in
temperate regions, follow seasonal trends. These ar-
thropods particularly thrive in mattresses and pillows
but carpets and rugs are also excellent reservoirs for
the mites [155].
Basic intervention to reduce exposure
An approach with different points of intervention
against facilitating factors, sources and accumulation of
mites in reservoirs is necessary to reduce exposure.
Intervention is entirely empirical and optimal if living in
an environment where there are no mites because of the
characteristics of the microclimate in terms moisture
and temperature, such as at high altitude locations
(>1500 m above sea level). Reproducing these conditions
at home often fails to provide the same results in terms
of absolute environmental control.
Ideally, the most effective measure is to reduce relative
humidity and keep it low between 35 and 50 % through-
out the year irrespective of external environmental
conditions.
High relative humidity actually constitutes the most
important factor favouring mite growth [156]. Mat-
tresses, pillows and sheets must be free of mite allergen,
carpet, rugs and other items that can become a reservoir
should be completely dispensed with [157].
In temperate climate homes, mite colonisation of mat-
tresses ordinarily occurs within 4 months of starting use,
regardless of the material of the mattress [158]. In other
words, a mattress that because of its characteristics is
claimed to be allergen-free does not exist. The most ef-
fective way to prevent mite colonisation is to sheathe
these items in covers made of fabric that is proof to mite
penetration, but also to allergens and to start using them
when the mattress is still new. For mattresses and pil-
lows that are already contaminated, the special fabric
cover can trap dust mites and allergens present and
prevent dispersal and contact with those who use them
[157]. Not all fabrics are the same, though and these
textiles which are mostly microfibers should allow the
passage of air and water vapour for proper perspiration
while keeping weave tension to ensure an average pore
diameter blocking the passage of allergens. These pores,
if of a diameter under 10 m, are able to block the pas-
sage of mite allergens, while those with a diameter less
than 6 pM, also block the Fel d 1 allergen from cat.
Fabrics that do not have these characteristics are not
recommended, as well as non-washable fabrics, which
accumulate allergen without the possibility of removing
it. Periodic washing of mattress covers at tempera-
tures > 60 °C allows eliminating mites anchored to the
weave [157].
Intervention through ad hoc pillow and mattress
covers should be extended to all pillows and mattresses
(used by siblings etc.) present in the same room as the
child.
A recent meta-analysis suggests that the use of anti-
mite mattress and pillow covers, although effective in re-
ducing the levels of exposure to mites, does not ensure
the complete prevention of the development of allergic
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disease or a reduction in the extent of the symptoms
[159, 160]. In other words, a single intervention does
not guarantee the absolute effectiveness of environ-
mental prophylactic measures and using a stepped,
multifaceted approach that considers several aspects is
probably better [161, 162]. Areas considered as allergen
sources should be vacuumed regularly and thoroughly
at least once a week to prevent the growth of mites, es-
pecially in homes with carpeting [163]. To be effective,
vacuum cleaning should capture the particles which
carry the dust mite allergens and prevent their disper-
sion. Suction alone does not eliminate all the mites, as
they are often well anchored to textiles, but it is effect-
ive to remove faecal particles which are highly aller-
genic. Air intake filters (the so-called high-efficiency
particulate air filters, HEPA) are regarded as essential
hoovering equipment as they are able to retain aller-
genic particles, thereby avoiding their re-suspension
and fall-out [157].
Physical measures such as freezing, heat and drying
(for blankets, sheets and even toys) should theoretically
be effective, as mites are killed by extremes of
temperature (below −20 °C and above 60 °C). However,
randomised clinical trials have yet to show a benefit of
these measures. Therefore, their use can be recommended
but is considered optional [157]. The use of acaricides is
not recommended as their effectiveness in prevention
does not warrant this type of intervention [157].
Are there specific tests to measure the load of environ-
mental allergen?
Tests for the measurement of mite allergens in the
environment are commercially available (on line “Home
dust mite test kits”). These methods measure the levels
of guanine and specific allergens using polyclonal and
monoclonal antibodies. Currently, this approach is
limited to research setting and should not be used in
clinical practice.
Conclusions
Primary prevention of IgE-mediated sensitisation to
dust mite allergens consists in avoiding persistent and
complete exposure to allergen for as long as possible, es-
pecially in the early years of life. While very effective
prophylaxis can be observed in regions with a dry climate
and altitude in the mountainous regions (1500 m above
sea level) where the mites do not survive, the complete
elimination of allergen exposure in homes located in
areas where mites are prevalent is difficult [164].
Even if exposure could be completely avoided within
the domestic environment, intermittent exposure occur-
ring elsewhere during the day (such as grandparents’
home, kindergarten, school or even in the street) can
still lead to dust mite allergen sensitisation [165–167].
Accordingly, many attempts at primary prevention
against mites cannot be effective. A correlation has been
demonstrated between the extent of allergen exposure
and risk level for sensitisation [168]. Therefore, the
amount of exposure to mite allergens should always be
reduced as much as possible [169] Table 1 and Box 7.
Box 7: Recommendations for action to reduce mite
allergen exposure.
Can allergic disease be avoided?
The aim of secondary prevention is to reduce the risk
of developing asthma and rhinitis in children already
sensitized to mites, usually during the early years of life
[170]. Several longitudinal studies have shown that
allergen exposure avoidance through “environmental
prophylaxis” reduces the risk of developing the disease
in a dose-dependent manner, particularly if this is asso-
ciated with a number of other interventions [170].
Moreover, the relationship between allergen exposure
and the development of disease appears to be influ-
enced by other contributing factors, such as contact
with other allergens, irritants and pollutants, such as
tobacco smoke or moulds [171].
- Reduce the level of relative humidity in the house, keeping it at
around 50 %. Use hygrometers and, possibly, a dehumidifier;
- Use pillow and mattress covers and cushion covers made of fabric
labelled “antimite”;
- Eliminate allergen sources/reservoirs such as carpets, rugs, curtains,
stuffed animals;
- Hoover periodically with a vacuum-cleaner that can retain allergen
in a HEPA filter;
- A multifaceted approach that includes all the previously described
measures is likely to be more effective and is thus recommended;
- Measures targeted at the physical elimination of mites (washing at
high temperatures > 60 ° C, freezing, drying) are theoretically effective
and can be recommended but clinical trials are lacking that show
their effectiveness;
- The use of acaricides is not recommended (limited effectiveness
and possible toxicity)
Table 1 Evidence of recommendation for anti-mite measures
Action on Type of intervention Level
recommendation
Facilitating factors Hygrometer Strong
Dehumidifier Strong
Central air conditioner None
Allergenic source Dry Strong
Acaricides Not recommended
Freezing None
Reservoir HEPA vacuum cleaners Strong
Pillowcases, mattress Strong
Pillowcases, pillow Strong
Kit for quantitative evaluation Poor
Denaturing agents Not recommended
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Many scientific studies have shown the importance of
environmental prophylaxis for children in whom aller-
gic disease has already developed. A global approach
contributes to more effective intervention, especially if
the effect of other factors that should be reduced or
eliminated is taken into account. The avoidance of dust
mite allergens in subjects with allergic disease is a
tertiary prevention intervention which leads to a de-
creased incidence of exacerbations in asthma and rhin-
itis, a marked improvement of symptoms, a decrease in
bronchial hyper responsiveness and a reduced use of
medications [157].
What messages are transmitted to the patient in terms
of environmental exposure and prevention possible?
Prevention of allergic diseases by modulating exposure
to dust mites requires strategy and is not limited to
recommendations steps. For this reason, the following
recommendations which address issues of primary, sec-
ondary and tertiary education are to be used in conjunc-
tion with the accompanying tables detailing individual
components of preventive action and should be dis-
cussed with parents in order to integrate them with their
values and preferences. This recommendation is issued
after due consideration of the available evidence.
Recommendations
Introduction
Primary prevention is difficult to achieve in our lati-
tudes as, even if environmental prophylaxis is the most
thorough, intermittent exposure to allergen (also outside
the home) can still cause sensitisation. Reduction of
exposure (and also of intermittent exposure) decreases
the odds of developing symptoms of allergic rhinitis
and asthma in children already sensitised to dust mites.
Limited exposure to mite allergen improves the
clinical status of sensitised children with respiratory
or skin disease (atopic dermatitis).
Recommendation Primary prevention of mite sen-
sitisation is possible only through a comprehensive
environmental monitoring strategy that must be
assessed on a case by case basis and discussed in de-
tail with the family.
Exposure to pets
Question 14. Is it advisable to have a pet in the house
for the prevention of allergic disease in children at high
risk of allergy?
Exposure to furry pets can lead to the development of
specific IgE antibodies (allergic sensitisation) in suscep-
tible individuals. This can begin a process leading to
events such as allergic asthma and/or rhinitis, especially
if exposure is continuous. Actually, once a sensitized
individual develops allergic disease, contact with aller-
gen triggers symptoms is often associated with poorly
controlled disease. Thus, the identification of exposure
sources and their removal can be considered as
treatment [172]. In the case of pets, there are many and
conflicting data about whether early and continued al-
lergen exposure (especially in the first 3 months of life)
may exert a protective action against sensitisation (pri-
mary prevention).
However, most studies are observational and their re-
sults are influenced by the fact that pets are more rarely
kept in homes with a family history of atopy than where
there is none. A recent review of longitudinal studies
concluded that the relationship between exposure and
risk of atopy is controversial. Results from the included
cohort studies seem to indicate that exposure to dogs
during childhood protects from the development of dog
allergen sensitisation itself [173]. In conclusion, there is
evidence that the first year of life represents a critical
period where exposure to dogs or cats can affect sensi-
tisation to pet animal allergen [174]. Although exposure
to high allergen levels may theoretically reduce the risk
of atopy, this reduction is not sufficient per se to recom-
mend pet-keeping as prevention for allergic sensitisation.
However, there is no recommendation to remove house-
hold animals from the home in order to prevent atopy.
In secondary prevention (i.e., when a child is already
sensitized) exposure should be minimised in order to
eliminate the risk of progression of disease to asthma
and rhinitis. In tertiary prevention, exposure to pet aller-
gens should be minimised in order to reduce the risk of
exacerbation of asthma or rhinitis symptoms. In children
with an allergy clearly related to pet exposure, contact
with their animal can also be minimized. Levels of inter-
vention if the patient is already sensitised: the removal
of the animal from the home is recommended to reduce
the total level of exposure, even if the allergen load in
the domestic environment gradually decreases, and par-
ticularly in the case of cat allergy. The characteristics of
the cat or dog itself, such as hair length, sex, breed, re-
productive status and the time it spends inside the home
cannot be associated with environmental allergen load
[175]. Data on the effectiveness of such measures of dog
or cat castration are inconsistent; for these interventions
have never been studied” or “for these interventions are
controversial”. Recommendation for this procedure in
order to reduce allergen exposure [172]. Global inter-
vention in the primary prevention of cat or dog sensi-
tisation is clearly preferable, but has already been shown
to be controversial.
Here we only considered the clinical aspects of pet al-
lergy in formulating these conclusions, and purposely
did not address other issues, such as zoonotic risk or the
emotional implications for children having to deliber-
ately or unintentionally part with their animal. These as-
pects should always be taken into account when
providing advice to families. Once that has been estab-
lished to raise awareness, subsequent exposure can
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determine disease progression through exacerbation and
reduced control. If removing the animal is not feasible
(recommended action, ref. #1), implementing a series of
measures designed to limit the level of allergen exposure
should be considered [172, 176]. These measures, if
implemented globally, can reduce exposure. With the
animal still present at home, a series of stringent steps is
required to achieve benefits [176]. These include the re-
moval of allergen reservoirs, restraining the animal out
of the house (again) or at least out of the bedroom area
of the house, regularly bathing the animal [177, 178], im-
proving home ventilation, and considering the possibility
of pillow and mattress cover use for bed hygiene. There
is no evidence that the use of products applied to the
animal’s fur is able to reduce the allergenicity of pets.
Recommendation. A pet is not recommended in
order to prevent sensitisation to animal-derived
allergens.
Indoor air quality and smoking
Question 15. Which of indoor air pollutants are the
main risk factors for the development of allergies in
children?
Indoor air quality is affected by both external and in-
ternal sources of pollution. Pollutants can be the result
of combustion processes (e.g., nitrogen dioxide, NO2) or
may be released from building materials, furniture and
commonly used home cleaning products (e.g., volatile
organic compounds, VOCs). In addition, outdoor pollut-
ants can enter homes and accumulate within confined
spaces. Thus, the indoor environment makes a significant
contribution to total exposure to pollutants [179, 180] and
indoor environmental pollutants, tobacco smoke (environ-
mental tobacco smoke, EU ETS) and household allergens
- especially dust mites, mould and dog and cat epithelia -
are the main risk factors for the development of allergy
in children [181].
Significantly, Western children and adolescents spend
most of their time indoors and therefore all interven-
tions designed to reduce exposure to these environmen-
tal risk factors as much as possible are an important
opportunity for prevention [182, 183]. Schools are an in-
door environment of particular interest: school environ-
ments are crowded places where different types of
allergens can persist for a long time. In Europe, the
Health Effects of the School Environment (HESE) pilot
study and the School Environment and Respiratory
Health of Children (SEARCH) study evaluated the ef-
fects of pollution on the health of school children. In the
HESE study, which was carried out in Sweden,
Denmark, Norway, France and Italy (Siena and Udine)
and included more than 600 children (mean age
10 years), a significant associations was found between
exposure to > 1000 ppm CO2 concentrations and risk of
dry cough, nocturnal cough and rhinitis.
Moreover, decreased nasal patency has been observed
in children exposed to >50 mg/m of particulate matter
(PM10) in the classroom [181]. The analysis of the data
collected during the study HESE also suggested that
classroom levels of mould > 300 CFU (colony forming
units) per cubic meter of air exposed children to an
increased risk of nocturnal dry cough [184, 185].
Recommendation In Western countries, children
and adolescents spend most of their time in indoors:
all interventions designed to reduce exposure to risk
factors as much as possible should include tobacco
smoke and indoor allergens (house dust mites,
moulds and dog and cat epithelia in particular) rep-
resent an important opportunity for prevention.
Question 16. Why is exposure to second-hand
smoke harmful?
Cigarette smoking is the main source of air pollution
indoors. Exposure to passive smoking in children is
associated with an increased risk of several diseases,
such as sudden infant death syndrome (SIDS), respira-
tory infections (bronchitis, bronchiolitis, pneumonia,
tonsillitis and pharyngitis), adenoidal hypertrophy,
impaired lung function (asthma), acute otitis media and
increased severity and risk of respiratory syncytial virus
infection [186]. Tobacco smoke contains more than
4000 chemical, 250 of which are known to be harmful
and 50 carcinogenic. The main constituents of tobacco
smoke that harm the respiratory apparatus include car-
bon monoxide, nitrogen oxide, formaldehyde, hydrogen
cyanide, sulphur dioxide, nitrosamines, nicotine, heavy
metals (lead, cadmium, nickel) and benzopyrene [187].
The effects of these chemicals are mediated by irritant,
mutagenic and immunological mechanisms that are
directly able to intervene in several pro-inflammatory
pathways (HPr kinase, ERK1/2, JNK, nF-kB) [188].
Numerous studies have shown that many of the
harmful effects of smoking are associated to its ability
to interfere with the functionality of immune system
cells, although the mechanism of action is not yet
fully understood [189].
Passive smoking plays an immunosuppressive role
by reducing Th1 cellular responses and increasing the
Th2-type response, especially when exposure occurs
during the first months of life [190].
There is evidence that cigarette smoking can cause al-
terations in both innate immunity (through reducing
dendritic cell and NKC function) and the adaptive arm
of immunity, (by interfering with the action of T lym-
phocytes) [191]. It has been shown that exposure to
second-hand smoke causes a marked reduction of T-
lymphocytes capable of producing IFnγ in children,
thereby favouring the onset of recurrent respiratory in-
fections [192]. It is therefore clear that passive smoking
is an exacerbation risk factor in asthmatic children
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and is strongly linked to poor symptomatic control,
higher medication consumption and reduced lung
function [193].
Recommendation. Cigarette smoking is the main
source of indoor air pollution. The harmful effects of
smoking are mediated by irritant, mutagenic and
immunological mechanisms which promote the
development of many diseases. It is essential to be
aware of smoke-related diseases and to promote a
smoke-free environment for children.
Question 17. Does exposure to passive smoking
promote the development of allergic sensitisation?
This is a hotly debated topic. The association between
exposure to smoking in childhood and risk of atopic sen-
sitisation has been extensively studied, but the literature is
not univocal.
Numerous studies have been conducted to evaluate
whether exposure to second-hand smoke can increase
the risk of allergic sensitisation in a dose-dependent
manner, especially with regard to allergens to which the
child is exposed from the first months of life (dust mites,
cat epithelium, food allergens).
One of the first studies of this topic showed that
smoking in pregnancy is associated with increased levels
of IgE in umbilical cord blood [194]. A multicenter study
of 342 German children showed that a correlation
existed between passive smoking and sensitisation to
food allergens, but not between smoking and sensitisa-
tion to aeroallergens [195]. In 2008, Lannero and
colleagues showed that early life exposure to tobacco
smoke is associated with increased risk of atopy and is
dose-dependent [196].
However, more recent studies offer conflicting evi-
dence, with some finding a reduced allergic sensitisation
prevalence among subjects exposed to smoke, while
others reported an increased risk of sensitisation, and
others still found none [197]. In view of these data, fur-
ther studies are needed to clarify the causes and patho-
physiological basis of the correlation between passive
smoking and atopic sensitisation.
Despite the possibility that passive smoking favours
the development of allergic sensitisation, it is now clear
that exposure to smoke results in an extremely harmful
effect on children’s respiratory function. In an extensive
meta-analysis published in Pediatrics, Burke and col-
leagues considered 79 prospective studies and concluded
that exposure to second-hand smoke causes an increase
of at least 20 % in the incidence of wheezing and asthma
in children [198].
Recommendation. The association between expos-
ure to smoking in childhood and risk of atopic
sensitisation has been extensively studied, but the
literature offers no consensus on this topic. How-
ever, the severity of smoke-related diseases suggest
recommending absolute avoidance of exposure to
second-hand smoke, regardless of the possibility
that smoking may promote allergic sensitisation.
Question 18. What are the prevention strategies to
protect children and adolescents from smoking?
According to the World Health Organization (WHO),
smoking is the leading cause of preventable deaths
worldwide and is responsible for more than 5 million
people dying from cancer, cardiovascular and respiratory
disease every year.
More than 50 % of children are currently exposed to
second-hand smoke in the home, especially in families
of lower socioeconomic status. Interventions on parents
and other household members have therefore a positive
effect on children. Children are particularly affected by
exposure to second-hand smoke because of the inad-
equate capacity of parents to create a smoke-free envir-
onment both at home and elsewhere [199].
Paediatricians have a fundamental role in promoting
the health of children and adolescents. In regard of
smoking, paediatricians are facing a twofold challenge:
on the one hand they have to make caregivers aware of
the dangers of exposure to second-hand smoke for chil-
dren, on the other they have to inform adolescents re-
garding the risks associated with active smoking [199].
In order to achieve such an effective prevention strategy
it is important to find out how children are exposed to
smoke. In preventive medicine, we usually distinguish be-
tween first-, second- and third-hand smoking. First-hand
smoking is active smoking. It might seem less relevant for
paediatric patients, however, as WHO data show that ado-
lescence is the age when most smokers develop the habit.
Second-hand smoking is the so-called “passive smoking”,
defined as the involuntary inhalation of substances from
cigarettes, pipes or cigars smoked by other individuals.
Third-hand smoking, lastly, consists in being exposed
to residues from smoking remaining in the environment,
on clothes, furniture, car seats, etc. To give one example,
a mother who lights up on the balcony of the house so
as not to pollute the home environment will prevent dir-
ect exposure of her child to cigarette smoke, though not
to third-hand smoke since residues deposited on her
clothes which can be subsequently breathed in by her
child.
Thus, it is important not to forget that the effects of
tobacco smoke exposure are substantially identical even
when caregivers smoke far away from their children and
even from the domestic environment (e.g., at work, in
cars, on balconies and other outdoor spaces). In conse-
quence, it falls on the paediatrician to make families
aware of all types of potential exposure to tobacco
smoke. In order to reduce and, hopefully, wholly avoid
smoke exposure, a multidisciplinary approach is needed
and must enlist government, institutions and schools.
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Intervention must focus on eliminating smoking
among individuals of all ages. Primary prevention inter-
ventions are intended to reduce tobacco supply for, and
access to, minors and promote motivational campaigns.
The most effective intervention is to discourage active
smoking in adolescents. The main measures is targeted
especially on health information and education in
schools, on the prohibition of smoking in all school
buildings and areas open to the public. It is important to
ban cigarette advertising and sales directed at minors, to
restrict adult smoking and to increase duties on ciga-
rettes. It should be also stated the importance of refer-
ring smoker adolescens to a specific tobacco programm.
It is also worthwhile to remind caregivers that smok-
ing cessation can ameliorate their and their children’s
health. When primary prevention measures fail or a
smoking habit is already formed, secondary prevention
should be attempted in order to limit the smoking habit
of young people [200].
It has recently been observed that the use of so-called
“electronic cigarettes” has become widespread. Even if
these devices are able to help adult smoker to quit
smoking, little is known about their possible impact on
health as passive smoking. In the absence of safety data
regarding the effects of exposure to electronic ciga-
rette’s vapour, exposure is not recommended. It is also
important to recommend keeping all necessary imple-
ments for electronic cigarette smoking out of the reach
of children.
In the US, cases of poisoning are on the rise as chil-
dren may ingest the substances they contain [201].
Recommendation. Paediatricians have a fundamen-
tal role to play in the promotion of all aspects of
child and adolescent health. Facing the problems
caused by smoking, paediatrician encounter a two-
fold challenge: informing caregivers about the dan-
gers of child exposure to second-hand smoke and
educating adolescents about the risks associated with
active smoking.
Conclusion
Numerous studies have been conducted to identify fac-
tors that trigger allergic sensitization and possible pri-
mary prevention strategies.
Sometimes they gave incontrovertible results : Con-
sensus acknowledges them and clarifies what are the
interventions that can be implemented in the high
risk child.
In some cases, however, the search results are insuf-
ficient or conflicting and, translated into the clinical
practice, make difficult the task of the pediatrician.
In clinical activity we must therefore always remember
that he is guilty not only doesn’t do what would be
useful, but also do what is unnecessary. Do what is un-
necessary has a cost to society, the family and the child.
The lack of evidence of efficacy to the current state of
the art does not necessarily imply that some interven-
tions could not be effective in the future. If rigorous
studies will demonstrated efficacy, these interventions
would then be recommended.
Clinical work is difficult and fraught with potential er-
rors, even when carried out according to the most rigor-
ous scientific criteria. Outside of these criteria the clinic
becomes a risky practice, unpredictable in its conse-
quences. Disseminate and reiterate to pediatricians this
general concept is an additional merit of this Consensus.
Question 19. Why do moulds constitute an envir-
onmental risk factor for children?
Changes in room temperature, humidity and ventila-
tion play a fundamental role in the development and/or
exacerbation of the symptoms of bronchial asthma. In
particular, the exacerbation of asthma symptoms in chil-
dren is commonly related to increased environmental
humidity and exposure to moulds [202]. There are
several species of moulds, but the most common are
Alternaria, Cladosporium, Aspergillus and Penicillium.
Among these, Alternaria is certainly the one which has
been most studied [203].
Asthma and allergic rhinitis are strongly correlated
with mould exposure during the first year of life in
children and adolescents. The PATY study (Pollution
and the Young), has confirmed the positive relationship
between visible mould, asthma and sensitisation to in-
halant allergens [204]. In the Cochrane review published
by Sauni and colleagues, preventive interventions against
moulds have been shown to reduce (even if only
partially) the number of medical visits related to asthma
exacerbation [205]. Prevention of exposure to mould has
proved an important strategy to prevent allergic sensi-
tisation, but avoidance of allergen exposure becomes
crucial for the child with documented sensitisation.. The
following steps must be followed for allergic patients:
eliminate possible sources of moisture in basements
(e.g., underground pipe leakage or seepage), dehumidi-
fier use in damp areas of the house to keep humidity
levels below 50 %, and regularly changing air-
conditioner filters [206].
Recommendation. Asthma and allergic rhinitis are
strongly correlated with exposure to mould during
the first year of life in children and adolescents.
Prevention for exposure to mould has been demon-
strated to be important in preventing allergic sensi-
tisation. Avoidance of allergen exposure is crucial for
children with documented mould allergy.
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